on AMOEBA (EPA:ALMIB)
AMOEBA: Initiation of Coverage by KBC Securities and International Expansion
Amoéba, the French greentech company specializing in natural microbiological solutions, announced that KBC Securities has initiated coverage of its stock. The recommendation is Buy, with a target price of €1.70 per share, indicating an upside potential of over 80%. This move follows the EFSA's favorable opinion on its active substance.
The company recently entered into major agreements with Koppert for biocontrol and with Metron Technology in China for cosmetics. Amoéba hopes to expand its investor base with the help of KBC Securities' international expertise.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news